160 related articles for article (PubMed ID: 24142793)
1. A novel germline JAK2 mutation in familial myeloproliferative neoplasms.
Rumi E; Harutyunyan AS; Casetti I; Pietra D; Nivarthi H; Moriggl R; Cleary C; Bagienski K; Astori C; Bellini M; Berg T; Passamonti F; Kralovics R; Cazzola M
Am J Hematol; 2014 Jan; 89(1):117-8. PubMed ID: 24142793
[No Abstract] [Full Text] [Related]
2. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms.
Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R
Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of atypical mutations in exons 13 and 15 of JAK2 gene in myeloproliferative neoplasms.
Luo M; Tian T; Zhang Y; Zhang X; Xie J; Xu J; Ren W; Tian C; Wang J; Tan Y; Wang H; Chen X
Int J Lab Hematol; 2021 Jun; 43(3):e110-e113. PubMed ID: 33244866
[No Abstract] [Full Text] [Related]
4. Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.
McCormick SR; Higgins RR; Grutkoski PS; Bousquet M; Quelen C; Bartholomaus LM; Brousset P
Br J Haematol; 2015 Apr; 169(2):290-3. PubMed ID: 25316507
[No Abstract] [Full Text] [Related]
5. [JAK2 mutation and thrombosis - recommendations for screening].
Held M
Dtsch Med Wochenschr; 2012 Feb; 137(5):227. PubMed ID: 22278696
[No Abstract] [Full Text] [Related]
6. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.
Bellanné-Chantelot C; Chaumarel I; Labopin M; Bellanger F; Barbu V; De Toma C; Delhommeau F; Casadevall N; Vainchenker W; Thomas G; Najman A
Blood; 2006 Jul; 108(1):346-52. PubMed ID: 16537803
[TBL] [Abstract][Full Text] [Related]
7. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
Ma W; Kantarjian H; Zhang X; Yeh CH; Zhang ZJ; Verstovsek S; Albitar M
J Mol Diagn; 2009 Jan; 11(1):49-53. PubMed ID: 19074595
[TBL] [Abstract][Full Text] [Related]
8. Splenomegaly and the JAK2 V617F mutation.
Langabeer SE
Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
[No Abstract] [Full Text] [Related]
9. Germline RBBP6 mutations in familial myeloproliferative neoplasms.
Harutyunyan AS; Giambruno R; Krendl C; Stukalov A; Klampfl T; Berg T; Chen D; Milosevic Feenstra JD; Jäger R; Gisslinger B; Gisslinger H; Rumi E; Passamonti F; Pietra D; Müller AC; Parapatics K; Breitwieser FP; Herrmann R; Colinge J; Bennett KL; Superti-Furga G; Cazzola M; Hammond E; Kralovics R
Blood; 2016 Jan; 127(3):362-5. PubMed ID: 26574608
[No Abstract] [Full Text] [Related]
10. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.
Jäger R; Harutyunyan AS; Rumi E; Pietra D; Berg T; Olcaydu D; Houlston RS; Cazzola M; Kralovics R
Am J Hematol; 2014 Dec; 89(12):1107-10. PubMed ID: 25196853
[TBL] [Abstract][Full Text] [Related]
11. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
12. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
[No Abstract] [Full Text] [Related]
13. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
[TBL] [Abstract][Full Text] [Related]
14. CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
Smaili W; Doubaj Y; Laarabi FZ; Lyahyai J; Kerbout M; Mikdame M; Sefiani A
Curr Res Transl Med; 2017; 65(1):15-19. PubMed ID: 28340692
[TBL] [Abstract][Full Text] [Related]
15. Germline
Park HS; Son BR; Shin KS; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Leuk Lymphoma; 2020 Dec; 61(13):3251-3254. PubMed ID: 32762473
[No Abstract] [Full Text] [Related]
16. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.
Xiao Z; Zhang Y; Li L; Nie L; Yang L; Xu S
Haematologica; 2008 May; 93(5):787-8. PubMed ID: 18450736
[No Abstract] [Full Text] [Related]
17. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
18. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
[TBL] [Abstract][Full Text] [Related]
19. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
20. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
